1. "2003"
Formats
  1. Journal Article (1307)
  2. Meeting Abstract (493)
  3. Book Section (121)
  4. Conference Paper (13)
  5. Book Whole (8)
Groups
  1. Department of Medicine (530)
  2. Sloan Kettering Institute Faculty (484)
  3. GSK Faculty (459)
  4. Surgery (454)
  5. Molecular Pharmacology and Chemistry Program Faculty (302)
  6. Solid Tumor Oncology Division (245)

More Groups

People
  1. Steven Larson (53)
  2. Michael Kattan (52)
  3. Carlos Cordon-Cardo (38)
  4. Murray Brennan (37)
  5. Peter Scardino (35)
  6. David Klimstra (34)

More People

Years
  1. 2003 (1942)
Publications
  1. Blood (97)
  2. Journal of Clinical Oncology (64)
  3. Journal of Nuclear Medicine (53)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (53)
  5. Modern Pathology (47)
  6. Laboratory Investigation (44)

More Publications

Publishers
  1. Elsevier Inc. (182)
  2. American Association for Cancer Research (137)
  3. Elsevier Science, Inc. (126)
  4. Lippincott Williams & Wilkins (117)
  5. Nature Publishing Group (113)
  6. Springer (98)

More Publishers

Results (1942)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparison of the transcriptional regulation of classical and non-classical MHC class II genes
    Meeting Abstract

    Hake, S. B.; Tobin, H. M.; Steimle, V.; Denzin, L. K.
    FASEB Journal (2003)

    Fulltext@MSK | Save
  • Childhood thyroid cancers express insulin-like growth factor-1 (IGF-1) and the IGF-1 receptor (IGF1-R) and aggressive cancers are more likely to express IGF1-R
    Meeting Abstract

    Gydee, H. K.; O'Neill, J. T.; Patel, A.; Bauer, A. J.; Tuttle, R. M.; Francis, G.
    Pediatric Research (2003)

    Fulltext@MSK | Save
  • CD52 expression in acute leukemia and advanced MDS: 118 cases at Memorial Sloan-Kettering Cancer Center
    Meeting Abstract

    Gupta, S.; Lamanna, N.; Rose, R.; Maslak, P. G.; Weiss, M. A.
    Blood (2003)

    Fulltext@MSK | Save
  • A phase II study of stem cell mobilization with IV melphalan (60 mg/M-2) + G-CSF in multiple myeloma
    Meeting Abstract

    Gupta, S.; Costello, S.; Zhou, P.; Reich, L.; Hassoun, H.; Klimek, V.; Kewalramani, T.; Dhodapkar, M.; Fleisher, M.; Hedvat, C.; more...
    Blood (2003)

    Fulltext@MSK | Save
  • The BEXXAR (R) therapeutic regimen (Tositumomab and iodine I 131 tositumomab) can be safely administered to patients over the age of 70
    Meeting Abstract

    Gregory, S. A.; Zelenetz, A. D.; Knox, S. J.; Vase, J. M.; Kaminski, M. S.
    Blood (2003)

    Fulltext@MSK | Save
  • Activated, mutated B-Raf protein kinase requires the Hsp90 chaperone protein for folding and stability and is degraded in response to Hsp90 inhibitors
    Meeting Abstract

    Grbovic, O. M.; Basso, A. D.; Houghton, A.; Solit, D. B.; Rosen, N.
    Clinical Cancer Research (2003)

    Fulltext@MSK | Save
  • Incremental improvements in QOL related to changes in Hb in breast cancer (BC) patients (pts) receiving adjuvant chemotherapy (ADJCT) and QW epoetin alfa therapy
    Meeting Abstract

    Gralow, J. R.; Hudis, C. A.; Williams, D.
    Blood (2003)

    Fulltext@MSK | Save
  • Bexxar® (tositumomab and iodine I 131 tositumomab) is well tolerated and efficacious in heavily pretreated patients with non-Hodgkin's lymphoma (NHL) and mild thrombocytopenia
    Meeting Abstract

    Goldsmith, S. J.; Kostakoglu, L.; Wahl, R.; Alavi, A.; Divgi, C.; Hankins, J.; Zelenetz, A.; Kaminski, M.
    Journal of Nuclear Medicine (2003)

    Fulltext@MSK | Save
  • Newly defined epitopes for mouse tyrosinase demonstrate potent CD8+T-cell responses to xenogeneic immunization with tyrosinase
    Meeting Abstract

    Goldberg, S. M.; Guevara-Patiño, J. A.; Montgomery, S. C.; Perales, M. A.; Houghton, A. N.; Wolchok, J. D.
    Journal of Immunotherapy (2003)

    Fulltext@MSK | Save
  • Imaging EGFR expression with novel kinase-specific irreversible radioligands
    Meeting Abstract

    Glekas, A.; Doubrovin, M.; Ageyeva, L.; Balatoni, J.; Larson, S. M.; Bornmann, W.; Gelovani, J.
    Journal of Nuclear Medicine (2003)

    Fulltext@MSK | Save